Evelo Biosciences, Inc. (EVLO) News
Filter EVLO News Items
EVLO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVLO News Highlights
- EVLO's 30 day story count now stands at 3.
- Over the past 20 days, the trend for EVLO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest EVLO News From Around the Web
Below are the latest news stories about EVELO BIOSCIENCES INC that investors may wish to consider to help them evaluate EVLO as an investment opportunity.
Flagship-backed microbiome biotech Evelo to shut downThe company said it had not found “a viable alternative” to closing down in the months since it hit a clinical setback and laid off staff. |
Horizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Greetings, and welcome to Horizon Technology Finance Corporation Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being […] |
Q3 2023 Horizon Technology Finance Corp Earnings CallQ3 2023 Horizon Technology Finance Corp Earnings Call |
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug StudyEvelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate. |
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & MoreRegulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector. |
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study wit |
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal ax |
Evelo Biosciences Closes $25.5 Million Private PlacementRestructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (the “Company” or “Evelo”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private plac |
Evelo Biosciences Announces $25.5 Million Private PlacementCAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share, which would result in gross pro |
Major Benchmarks On Track For Strong End To JuneAll three major benchmarks are on the rise as the second quarter comes to a close, with big gains on the horizon. |